|
|
|
| Expression of Androgen Receptor and p53 In the Prognosis of Three-Negative Breast Cancer |
| WANG Zhan-mei,SONG Yu-hua,XUAN Tian-tian |
| Department of Oncology, Affiliated Hospital, the Medical College of Qingdao University, Qingdao 266000, Shandong |
|
|
|
|
Abstract 【Objective】To investigate the relationship between the expression of androgen receptor and p53 in the prognosis of three negative breast cancer.【Methods】From January 2010 to December 2011, the clinical data of 87 patients with TNBC (three negative group) and 231 patients without TNBC (non-three negative group) were collected. The expression of AR and p53 was detected by immunohistochemistry and its relationship with clinicopathological features and prognosis was analyzed .【Results】The positive rates of p53 and AR in the three negative group were 49.43 % (43/87) and 37.93 % (33/87), respectively, which were significantly higher than those in the non-three negative group p 33.77 % (78/231) and 27.3 % (63/231), the differences were statistically significant (χ2=9.451, P=0.025;χ2=8.287, P=0.031). The positive expression of AR was related to lymph node metastasis (P<0.05), the positive expression of p53 was related to histological grade and molecular type (P<0.05), there was no correlation between other markers and the positive expression of p53 and AR (P>0.05). The 5-year local recurrence rate and distant metastasis rate in the three negative group was significantly higher than those in the non-three negative group (P<0.05). The 5-year survival rate was significantly lower than that in non-three negative group (P<0.05).【Conclusion】The expression of p53 and AR in TNBC was up-regulated, which was related to the differentiation of tumor cells and the status of lymph node metastasis. p53 and AR can be used as predictors of prognosis in patients with breast cancer .
|
|
Received: 23 March 2017
|
|
|
|
|
|
[1] 邓智平,刘秋芳,宋张骏,等.三阴性乳腺癌患者综合治疗的预后分析[J].实用癌症杂志,2016,31(5):752-753.
[2] 智英辉,尼杰,田秀芳,等.雄激素受体在三阴性乳腺癌的表达及其预后意义[J].重庆医学,2012,41(27):2812-2815.
[3] 杨艳芳,李彦昕,姜战胜,等.P53和VEGF表达与三阴性乳腺癌预后的关系[J].中华普通外科杂志,2015,30(12):995-996.
[4] 智英辉,尼杰,田秀芳,等.153例三阴性乳腺癌的临床病理特征分析[J].山东医药,2012,52(6):61-62.
[5] 尼杰,智英辉,只向成,等.P53在三阴性乳腺癌中的表达及其与铂类化疗药物敏感性的关系[J].天津医药,2013,41(4):317-320.
[6] 雷雨,马钰.雄激素受体在三阴性乳腺癌患者中的表达及其对临床结局的影响[J].中国综合临床,2016,32(5):440-443.
[7] 张雁瑞,黄犁,姜辉,等.P53在三阴性乳腺癌中的表达及其意义[J].中国医药导报,2012,09(17):24-25.
[8] 陈凤霞.雄激素受体在三阴性乳腺癌发生发展中的作用[J].癌症进展,2013,11(4):337-340.
[9] Chae BJ,Bae JS,Lee A,et al.p53 as a specific prognostic factor in triple-negative breast cancer[J].Jpn J Clin Oncol,2009,39(4):217-224.
[10] 陈洪流.三阴性乳腺癌患者的临床特征及预后因素[J].中国老年学杂志,2013,33(23):5840-5841.
[11] 栗艳松.VEGF和P53在三阴性乳腺癌中的表达及临床意义[J].河北医药,2014,36(19):2903-2905.
[12] 张勤,刘红.P53在三阴性乳腺癌中的表达及临床意义[J].中国肿瘤临床,2011,38(4):214-217.
[13] Ahn S ,Cheney MD,et al.Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling[J].PLoS One,2014,9 (7):e103202. |
|
|
|
2018, Vol. 35 
